Theriva Biologics
TOVX
29 hedge funds and large institutions have $37.9M invested in Theriva Biologics in 2014 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
12% more funds holding
Funds holding: 26 → 29 (+3)
11% more capital invested
Capital invested by funds: $34.2M → $37.9M (+$3.71M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$6.14M |
| 2 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$3.14M |
| 3 |
MP
MSD Partners
New York
|
+$1.4M |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$242K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$121K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
-$491K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$282K |
| 3 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$265K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$71K |
| 5 |
Goldman Sachs
New York
|
-$53.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BA
26
BlackRock Advisors
Wilmington,
Delaware
| $16K | +$13.4K | +1 | New |
|
|
OC
27
Oppenheimer & Co
New York
| $15K | – | – | – |
|
|
BIM
28
BlackRock Investment Management
Wilmington,
Delaware
| $14K | – | – | – |
|
|
29
Bank of America
Charlotte,
North Carolina
| $9K | -$282K | -21 | -95% |
|
30
Citigroup
New York
| $4K | – | – | – |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| $3K | – | – | – |
|
32
Citadel Advisors
Miami,
Florida
| $1K | -$26.9K | -2 | Closed |
|
33
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
34
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $6 | – | – | – |
|
|
RA
35
Royce & Associates
New York
| – | -$491K | -32 | Closed |
|
|
36
Janney Montgomery Scott
Philadelphia,
Pennsylvania
| – | -$265K | -17 | Closed |
|
|
BCM
37
Bridgeway Capital Management
Houston,
Texas
| – | -$71K | -5 | Closed |
|
|
CCM
38
Check Capital Management
Costa Mesa,
California
| – | -$18K | -1 | Closed |
|
39
Creative Planning
Overland Park,
Kansas
| – | -$4K | – | – |
|
40
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$5K | – | – |
|
TOVX Hedge Fund Activity: Q4 2014 in Review
29 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q4 2014, worth a combined $37.9M — up 11% from $34.2M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new TOVX positions and 5 closed out — a net gain of 3 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $6.14M. The largest seller was Royce & Associates, exiting entirely with an estimated $491K sold.
- 29 institutional investors held Theriva Biologics (TOVX) as of Q4 2014, up from 26 in Q3 2014.
- Funds reported $37.9M of Theriva Biologics stock for Q4 2014, up 11% quarter-over-quarter.
- 8 funds opened new Theriva Biologics positions in Q4 2014 and 5 closed out, a net change of +3 holders.
- The largest Theriva Biologics buyer in Q4 2014 was Great Point Partners, an estimated $6.14M added.
- The largest Theriva Biologics seller in Q4 2014 was Royce & Associates, an estimated $491K sold.
Based on aggregated 13F filings for Q4 2014.